N/A
N=26
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Bottom Line
View on ClinicalTrials.gov: NCT05507333 ↗Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- pHyph generation II (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Gedea Biotech AB
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Cure Rate at Day 7-14 |
10; 16 | — |
| SECONDARY Continued Clinical Response to Treatment at Day 25 |
11; 2 | — |
| SECONDARY Combined Clinical and Mycological Cure at Day 7-14 |
16; 10 | — |
| SECONDARY Mycological Cure at Day 7-14 |
12; 14 | — |
| SECONDARY Mycological Cure at Day 25 |
3; 10 | — |
| SECONDARY Absence of Candida Hyphae in the Wet Smear |
11; 15 | — |
| SECONDARY Change in the Composite Vulvovaginal Signs and Symptoms (CVVS) Score From Screening to Day 7-14 |
7.46; 2.96 | — |
| SECONDARY Change in the Composite Vulvovaginal Signs and Symptoms (CVVS) Score From Screening to Day 7-14 - Proportions |
3; 23 | — |
| SECONDARY Proportion of Patients Having a Reduction in the Sum of the 3 Vulvovaginal Symptoms Scores (Itching, Burning, and Irritation) Over Time Compared to Screening |
6; 14; 15; 17; 16; 21 | — |
| SECONDARY Change in the Sum of the 3 Vulvovaginal Symptoms Scores (Itching, Burning, and Irritation) Over Time Compared to Screening |
-0.200; -0.560; -1.24; -1.40; -1.50; -2.48 | — |
| SECONDARY Usability, Measured by Patient Questionnaire on Day 6. |
3; 22 | — |
Summary
This is a multi-centre, multi-national study to evaluate the clinical performance and safety of treatment with Gedea Pessary in adult women with confirmed vulvovaginal candidiasis (VVC).
The study population will consist of post-menarchal, pre-menopausal females, 18 years or older, seeking care for VVC symptoms. A total of 26 patients are planned to be included in the study. On Day 0 (Screening, Visit 1), eligible patients will undergo a gynaecological examination, including collection of composite vulvovaginal signs-and-symptoms (CVVS) score data, and vaginal samples. Patients will be provided with 6 doses of Gedea Pessary that will be self-administered as a daily treatment (Days 0 to 5).
Patients will visit the clinic on Day 7 (+2 days, Visit 2) for gynaecological examinations, including collection of CVVS data for the assessment of clinical cure and reporting of AEs and concomitant medications. On Day 14 (±2 days, Visit 3), patients that did not have a clinical and mycological cure Day 7 will re-visit the clinic for additional gynaecological examinations, including collection of CVVS data for the assessment of clinical cure. Rescue treatment will be offered during visits 2 and 3, if necessary. Patients will have a final telephone follow-up on Day 25 (±3 days, Visit 4), for for reporting of AEs, concomitant medications and potential menstruation onset. Vaginal sampling for culture and sequencing, as well as vaginal pH measurements will be performed at the clinic on Day 0, Day 7, and Day 14. On Day 25, patients will self-perform vaginal swabs at home for sequencing and vaginal culture. Patient questionnaires for assessing VVC symptoms, will be used during the treatment period (Days 0 to 5), 1 day after the treatment (Day 6) and on Days 11 and 25. Usability will be assessed on Day 7, also via the patient questionnaire. The patient questionnaire will be based on an electronic patient reported outcomes (ePRO) system, i.e. a mobile application (ViedocMe™).
Eligibility Criteria
Inclusion Criteria
- Having decisional capacity and providing written informed consent.
- Adult, post-menarchal, pre-menopausal women, aged 18 years or older
- Diagnosis of VVC, defined as:
- Having a white or creamy vaginal discharge
- At least 2 of the following signs and symptoms of VVC that are characterised as at least moderate: itching, burning, irritation, oedema, erythema, or excoriation.
- KOH or saline preparation from the inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or budding yeasts.
- Negative urine pregnancy test at Screening.
- Refrain from using any intravaginal products (i.e. contraceptive creams, gels, foams, sponges, lubricants, or tampons, etc.) until Day 14.
- Refrain from sexual intercourse or use a condom until Day 7.
- Signed informed consent and willing and able to comply with all study requirements.
Exclusion Criteria
- Patients with known or apparent signs of other infectious causes of vaginal infection (BV, Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex, or human papillomavirus) at Screening.
- Patients who are pregnant or breastfeeding.
- Patients who were treated for VVC within 14 days prior to Screening.
- Patients who are currently receiving anti-fungal therapy unrelated to VVC or has taken anti-fungal therapy within 14 days prior to Screening.
- Patients who have received an investigational drug in a clinical investigation within 30 days prior to Screening.
- Known/previous allergy or hypersensitivity to any product constituent or fluconazole.
- Any medical condition that in the Investigator's judgements would make the patient unsuitable for inclusion.
- More than 3 previous VVC infections during the last 12 months.
Data sourced from ClinicalTrials.gov (NCT05507333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.